2916 North Miami Avenue
Suite 1000
Miami, FL 33127
United States
305 509 6897
https://verupharma.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 189
Nombre | Título | Paga | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Mitchell S. Steiner F.A.C.S., M.D. | Chairman, President & CEO | 885,32k | N/A | 1961 |
Dr. Harry Fisch F.A.C.S., M.D. | Vice Chairman & Chief Corporate Officer | N/A | N/A | 1959 |
Ms. Michele Greco | CFO & Chief Administrative Officer | 493,7k | N/A | 1959 |
Dr. K. Gary Barnette Ph.D. | Chief Scientific Officer | 676,27k | N/A | 1968 |
Mr. Samuel Fisch | Executive Director of Investor Relations & Corporate Communications | N/A | N/A | N/A |
Mr. Michael J. Purvis | Executive VP, General Counsel & Corporate Strategy and Secretary | N/A | N/A | N/A |
Mr. Kevin J. Gilbert CPA, J.D. | Executive Vice President of Corporate Development | N/A | N/A | N/A |
Mr. Martin Tayler | Executive Vice President of FC2 Global Operations | 180,51k | N/A | 1969 |
Mr. Philip R. Greenberg J.D. | Executive VP & Deputy General Counsel | N/A | N/A | N/A |
Dr. Domingo Rodriguez M.D. | Executive Vice President of Global Clinical Operations | N/A | N/A | 1962 |
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
El ISS Governance QualityScore de Veru Inc., a día 1 de mayo de 2024, es 10. Las puntuaciones base son Auditoría: 10; Tablero: 8; Derechos de los accionistas: 4; Compensación: 10.